Eugene Sullivan: Yeah, the only comment I’d make is that when patients have elevated eosinophils in their secretions, either speed up or nasal secretions, it doesn’t mean that all of this inflammatory cells RDS and of course, just means there’s a lot of them. And actually, there are a lot of neutrophils even in patients who have elevated eosinophils a lot of the inflammation, it is still neutrophilic driven. So I think there’s it’s still a reason to expect a benefit even in those patients. That’s why we didn’t like exclude eosinophil patients. That’s the only thing I want to clarify because sometimes and people think that when it’s elevating EDO’s, it’s at the expense of the neutrophils. But in that milieu and the inflammatory milieu, there are plenty of neutrophils there as well.
William Lewis: We need to the specific numbers that we have and they’re public. It was a follow-up.
Operator: Your next question comes from Andy Chen from Wolfe Research.
Unidentified Analyst: Hi, this [indiscernible] is on for Andy. Thanks for taking our question and congrats on the data. Just a couple of quick ones on our end. I guess how big is the existing arcade sales force? And then assuming brands are successful target sales force size there and that’s one. And then on PAH regarding the average improvement in six-minute walk distance from baseline of 43 meters, how should we interpret this data point? I know during the call. As mentioned, it’s a highly variable measure. So it’s difficult kind of interpret this. But would you say this is a modest or big success? Was there kind of an internal bar.
William Lewis: Sara, do you want to take the question on sales force expansion and Gene, you can take the one on the six-minute walk on TPIP?
Sara Bonstein: Sure. Happy to. Thanks for the question. Our existing sales force in the US, we have about 65, 70 reps existing in the US and we will look to expand that what we’ve said publicly 200 to 220 is what we’ve said publicly. We’ll share more on those details on the Commercial Day that we’ve alluded to throughout the Q&A session. What I would like to comment on is the immense crossover between ARIKAYCE and brensocatib and the synergies that we will have. ARIKAYCE, obviously, calls on pulmonologists and ID docs brenso, primary call is a pulmonologist. So it’s subject to very synergistic products that you don’t necessarily see. And so we’re really excited about being able to leverage the infrastructure. Gene, over to you.
Eugene Sullivan: Sure. So on the six-minute walk distance in the blended blinded of 43 meters, of course, we say this over and over again, it’s a very variable measure. And more importantly, we don’t know who’s on active and who’s on placebo. And so it’s very difficult to interpret 43 meters, but we are happy to see improvements. We’re seeing patients and improvements in those, you know, represent patients who were on active drug. That’s great. And the 43 meters would be plenty of the other point I want to make, though is that even at the end of this trial, it’s a larger trial than the PH-ILD study. But with 99 patients were not powered to see a statistically significant effect on six-minute walk distance even with the final unblinded data, we’ll get a point estimate, we’ll get a sense, but I just wanted to point out that even with 90, 99 patients or so, we know that it likely is not enough.
If you look at the pivotal trial for Tyvaso in PAH that was over 200 I think it was 230 or so patients to show a statistically significant benefit. So we see the improvement in the blended population. We don’t know who’s on active and who’s not, but we’re pleased with it as a good number. And there are patients who are clearly improving, and we’ll just have to wait to see the unblinded data.
Operator: And that concludes our Q&A session for today. And I would like to hand back to management for closing remarks.
William Lewis: Thanks very much, everyone, for joining us today.
Operator: This concludes today’s conference call. Enjoy the rest of your day, and you may now disconnect.
